Aniracetam
Cas No.: 72432-10-1
What is aniracetam?
Aniracetam is a derivative of piracetam, a compound with nootropic effects. Other names used include Ro-13-5057, Memodrin, Draganon, Sarpul, Ampamet, Referan. It is one of the representatives of racetams, which was synthesized in the 1970s. The compound is synthesized by replacing the amino group of piracetam with a methylated phenyl group. This allows for much better fat solubility. By supporting cerebral neurotransmission, the formula improves cognitive function, similar to phenylpiracetam, for example.
Use of aniracetam
Aniracetam is used as a preparation with nootropic effects. By affecting various neurotransmitter systems, the compound significantly improves concentration and memory. Since the compound exhibits neuroprotective effects, it can offset cognitive impairment occurring as a result of brain ischemia or injury. Another use of the Aniracetam pharmaceutical is to reduce anxiety and restlessness, as well as depressive states.
Mechanism of action
Aniracetam interacts with AMPA receptors, making them more sensitive to the effects of glutamate. This allows hippocampal neurons to release more norepinephrine. The compound also regulates the activity of NMDA receptors, which are sensitive to glutamate. Another mechanism of action of the product is its effect on acetylcholine receptors, as well as generating changes in the concentrations of such neurotransmitters as serotonin and dopamine. The product’s action profile depends on the area of the brain – the hippocampus, the amygdala nucleus or the cortex.
Aniracetam – dosage
The recommended dosage of aniracetam is 400 to 1,500 mg per day. It is best to take from smaller doses, such as 300-400 mg, and assess whether the response to the preparation is satisfactory. Since the product is highly fat-soluble, it is best to take it with a meal containing fat.
References:
- Isaacson JS, Nicoll RA. Aniracetam reduces glutamate receptor desensitization and slows the decay of fast excitatory synaptic currents in the hippocampus. Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10936-40; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC53047/
- Canonico V, Forgione L, Paoletti C, Casini A, Colonna CV, Bertini M, Acito R, Rengo F. Efficacia e tollerabilità dell’aniracetam in pazienti anziani affetti da deterioramento mentale primitivo e secondario [Efficacy and tolerance of aniracetam in elderly patients with primary or secondary mental deterioration]. Riv Neurol. 1991 May-Jun;61(3):92-6; https://pubmed.ncbi.nlm.nih.gov/1767242/
- Nakamura K, Kurasawa M Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism . Eur J Pharmacol. (2001); https://pubmed.ncbi.nlm.nih.gov/11412837/
- Senin U., Abate G., Fieschi C., Gori G., Guala A., Marini G., Villardita C., Parnetti L. Aniracetam (Ro 13-5057) in the treatment of senile dementia of Alzheimer type (SDAT): results of a placebo controlled multicentre clinical study. European Neuropsychopharmacology, Volume 1, Issue 4, December 1991, Pages 511-517; https://pubmed.ncbi.nlm.nih.gov/1822317/
